IndustryCompany release

PTC Therapeutics guides to $1.29-1.32bn 2026 revenue as Sephience PKU launch drives portfolio

🇺🇸 Ptc Therapeutics, Inc. (PTCT) · Thu 29 Oct 2026

The rare disease company's October corporate deck sets out 2026 revenue and cost guidance, reports $2.1bn in cash and names Phase 3 votoplam in Huntington's disease as a priority.

PTC Therapeutics has published an October 2026 corporate presentation outlining its rare disease portfolio, with Sephience for phenylketonuria (PKU) given the leading position.

For 2026, the company guides to product revenue of $960-990m and total revenue of $1.29-1.32bn. It expects non-GAAP operating expenses of $680-720m. The deck reports cash of $2.1bn as of 30 September 2026 and says the company is targeting cash flow breakeven during 2026.

On the clinical side, the presentation cites data from the AMPLIPHY study showing a 70.3% greater reduction in blood phenylalanine (Phe) with Sephience than with BH4. The summary does not give further detail on the study design or the comparison, and the full source text was not available for this report.

The deck also lists the Phase 3 programme for votoplam in Huntington's disease as a company priority. No timelines or data readouts for that programme are given in the material reviewed.

What it means for your team

  • Market-access teams should note the company's emphasis on the AMPLIPHY comparison with BH4, which may shape how Sephience is positioned against existing PKU therapy in payer discussions.
  • The figures are company guidance in a corporate presentation, not regulatory findings; the underlying AMPLIPHY data should be checked against the primary publication or filing before use.
  • Regulatory and PV watchers should follow votoplam's Phase 3 Huntington's disease programme, which the company has flagged as a priority.

Company's press release (SEC filing): Ptc Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Ptc Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →